Avelumab and Merkel Cell Carcinoma: A Causation Analysis

From General Health Information to Targeted Pharmacovigilance

Legacy health information platforms have long served as trusted repositories for general wellness guidance, disease prevention tips, and lifestyle medicine. These resources typically address broad public concerns—nutrition, exercise, vaccination schedules—without delving into the specific pharmacovigilance questions that arise in specialized clinical or occupational settings. The foundational principle has been to empower individuals with accessible, non-specialist knowledge that supports informed decision-making in everyday life. Transitioning from this general health context to a more targeted inquiry requires a shift in focus toward therapeutic agents and their potential unintended effects. In particular, the introduction of immunomodulatory drugs such as Avelumab—a PD-L1 inhibitor used in oncology—raises nuanced questions about drug safety and disease etiology. While Avelumab is indicated for the treatment of Merkel Cell Carcinoma, a rare and aggressive skin cancer, the question of causation in the opposite direction demands careful scrutiny. This pivot moves the discussion from population-level health education to a precise, exposure-oriented risk assessment, where the central concern becomes whether administration of Avelumab itself could contribute to the development or progression of Merkel Cell Carcinoma. Such an inquiry is especially relevant for healthcare professionals, researchers, and patients navigating the complexities of immunotherapy and its long-term consequences.

Avelumab and Merkel Cell Carcinoma: A Bridge from General Context to Specific Evidence

Building on the legacy of general health information, we now focus on the specific question: Does Avelumab cause Merkel Cell Carcinoma? Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). It is associated with chronic ultraviolet light exposure and the Merkel cell polyomavirus (https://pubmed.ncbi.nlm.nih.gov/35877101/). The incidence of MCC is increasing, and the disease carries high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Clinically, MCC presents as a rapidly growing, painless, firm, dome-shaped nodule on sun-exposed skin, often mistaken for a benign cyst or lipoma. Diagnosis requires histopathological examination with immunohistochemistry, typically showing cytokeratin-20 positivity and neuroendocrine markers. Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It functions as an immune checkpoint inhibitor and is approved in the USA, EU, and Japan for the treatment of metastatic MCC, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the JAVELIN Merkel 200 phase II trial, where confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is thus the first therapeutic agent specifically approved for this indication (https://pubmed.ncbi.nlm.nih.gov/29799096/).

Mechanistic Pathways and Clinical Evidence

The question of whether avelumab causes MCC must be examined through the lens of its mechanism and clinical context. Avelumab is an anti-PD-L1 inhibitor that blocks the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby enhancing the immune system's ability to recognize and attack cancer cells. This mechanism is therapeutic for MCC, not causative. However, avelumab is known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). Reported irAEs include hypercalcemia due to sarcoidosis reactivation, which was managed with corticosteroids while avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). There is no evidence in the provided sources that avelumab directly induces de novo MCC. Instead, the drug is used to treat existing MCC. The evidence indicates that avelumab is a treatment for MCC, not a cause. In patients with metastatic MCC, immune checkpoint inhibition with avelumab has shown response rates up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For avelumab-refractory patients, alternative treatments such as ipilimumab plus nivolumab have been evaluated (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). In a multicenter study, three out of five avelumab-refractory patients responded to combined ipilimumab plus nivolumab according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/).

Causation Considerations and Risk Context

For patients who develop MCC while receiving avelumab, the temporal relationship must be carefully assessed. Avelumab is indicated for metastatic MCC, meaning patients already have the disease at the time of treatment initiation. Therefore, any new or progressive MCC during avelumab therapy is likely due to disease progression or treatment resistance, not drug causation. The evidence shows that avelumab-refractory MCC is a recognized clinical scenario, and treatment options for such patients are being investigated (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). The timeline between avelumab exposure and harm is relevant only in the context of adverse events, not MCC causation. Immune-related adverse events can occur during treatment, as seen with sarcoidosis reactivation (https://pubmed.ncbi.nlm.nih.gov/31543781/). However, no evidence links avelumab to the development of MCC. The drug's approval and use are based on its efficacy in treating MCC, and the literature consistently describes avelumab as a therapeutic agent for this cancer. Warnings for avelumab appropriately focus on immune-related adverse events, not on causing MCC. The prescribing information for avelumab includes warnings about irAEs such as pneumonitis, hepatitis, colitis, endocrinopathies, and nephritis. There is no evidence in the provided sources that avelumab carries a warning for causing MCC, as this would be contrary to its approved indication. The risk of MCC progression during avelumab therapy is addressed through clinical monitoring and alternative treatment strategies for refractory disease.

Conclusion

Based on the provided evidence, avelumab does not cause Merkel cell carcinoma. Rather, it is an approved treatment for metastatic MCC. The drug's mechanism of action as a PD-L1 inhibitor is therapeutic, and no mechanistic pathway linking avelumab to de novo MCC is supported by the evidence. Patients who develop MCC while on avelumab are likely experiencing disease progression or resistance, not drug-induced carcinogenesis. Warnings for avelumab appropriately address immune-related adverse events, and there is no indication that the drug is a causative agent for MCC.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does Avelumab cause Merkel Cell Carcinoma?

No, Avelumab is an approved treatment for metastatic Merkel Cell Carcinoma (MCC). It works by blocking PD-L1 to enhance the immune response against cancer cells. There is no evidence that Avelumab causes de novo MCC; rather, it is used to treat existing MCC.

What should I do if I develop Merkel Cell Carcinoma while on Avelumab?

If you develop MCC while on Avelumab, it is likely due to disease progression or treatment resistance, not drug causation. Consult your healthcare provider for evaluation and alternative treatment options, such as ipilimumab plus nivolumab, which have shown efficacy in avelumab-refractory patients (https://pubmed.ncbi.nlm.nih.gov/33439294/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.